Cannabidiol for the treatment of cannabis use disorder: Phase IIa double-blind placebo-controlled randomised adaptive Bayesian dose-finding trial

BACKGROUND: There is a substantial and unmet clinical need for pharmacological treatment of cannabis use disorders. Cannabidiol (CBD) could offer a novel treatment but it is unclear which doses might be effective or safe. METHODS: Participants meeting DSM-5 cannabis use disorder criteria were alloca...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet Psychiatry
Autors principals: Freeman, Tom P, Hindocha, Chandni, Baio, Gianluca, Shaban, Natacha DC, Thomas, Emily, Astbury, Danica, Freeman, Abigail M, Lees, Rachel, Craft, Sam, Morrison, Paul D, Bloomfield, Michael AP, O’Ryan, Dominic, Kinghorn, Jane, Morgan, Celia JA, Mofeez, Ali, Curran, H Valerie
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7116091/
https://ncbi.nlm.nih.gov/pubmed/32735782
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2215-0366(20)30290-X
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars